Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

Added value of subtraction imaging in detecting arterial enhancement in small (

(2012) Chansik An et al.   EUROPEAN RADIOLOGY

MRI assessment of percutaneous ablation of liver tumors: Value of subtraction images

(2012) Servet Tatli et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas

(2012) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Use of Dynamic Phase Subtraction (DPS) Map in Dynamic Contrast-Enhanced MRI of the Breast

(2011) Akio Ogura et al.   JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab

(2011) B. M. Ellingson et al.   NEURO-ONCOLOGY

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

(2010) Jeffrey J. Raizer et al.   CANCER

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiographic patterns of relapse in glioblastoma

(2010) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

(2009) Maurizio Zangari et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Antiangiogenic therapies for high-grade glioma

(2009) Andrew D. Norden et al.   Nature Reviews Neurology

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma

(2008) Marc C. Chamberlain   JOURNAL OF CLINICAL ONCOLOGY

In Reply:

(2008) James J. Vredenburgh et al.   JOURNAL OF CLINICAL ONCOLOGY

Time course of imaging changes of GBM during extended bevacizumab treatment

(2008) Suchitra Ananthnarayan et al.   JOURNAL OF NEURO-ONCOLOGY

Novel anti-angiogenic therapies for malignant gliomas

(2008) Andrew D Norden et al.   LANCET NEUROLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme

(2008) David Schiff et al.   Nature clinical practice. Oncology